Sugi Predict

Sugi Predict / Compounds / SCHEMBL27076571

SCHEMBL27076571

SCHEMBL27076571

O=C(ON1C(=O)CCC1=O)c1ccc(F)nc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.38
▸ SLC18A3 Q16572 1/20 0.35
▸ KCNQ3 O43525 1/20 0.35
▸ KCNQ2 O43526 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ MGLL Q99685 3/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ FAAH O00519 1/20 0.33
▸ NLRP3 Q96P20 1/20 0.33
▸ CHIT1 Q13231 1/20 0.33
▸ CHIA Q9BZP6 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ PDE3B Q13370 1/20 0.32
▸ PDE3A Q14432 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4758814 0.82 HDAC1 (0.45) MAPK1KDM4EL3MBTL1MAPTNPC1
SCHEMBL16938414 0.82 GABRP (0.49) MAPK1EPHX2MGLLKDM4EL3MBTL1
SCHEMBL1509187 0.81 MAPK1 (0.41) MAPK1MGLLKDM4EL3MBTL1NPC1
SCHEMBL300884 0.80 CA12 (0.42) MAPK1MGLLKDM4EMAPTCA12
SCHEMBL30914672 0.79 MAPK1 (0.40) MAPK1MGLLKDM4EL3MBTL1RAB9A
SCHEMBL12488583 0.79 MAPK1 (0.67) MAPK1KDM4EL3MBTL1MAPTNPC1
SCHEMBL1445644 0.79 MAPK1 (0.40) MAPK1MGLLKDM4EL3MBTL1RAB9A
Hydrochloric Acid SCHEMBL5087052 0.79 MAPK1 (0.40) MAPK1MGLLKDM4EL3MBTL1RAB9A
SCHEMBL1696262 0.79 KDM4E (0.42) MAPK1MGLLKDM4EFAAHMAPT
SCHEMBL159204 0.79 KDM4E (0.42) MAPK1MGLLKDM4EFAAHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382629-A1 HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN THE JOHNS HOPKINS UNIVERSITY 2024-11-21 — — US disclosed
EP-4313049-A1 HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN The Johns Hopkins University (US) 2024-02-07 — — EP disclosed
CN-117255685-A Heterodivalent and homodivalent agents targeting fibroblast activation protein alpha and/or prostate specific membrane antigen 约翰霍普金斯大学 2023-12-19 — — CN disclosed
WO-2022212958-A1 HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN THE JOHNS HOPKINS UNIVERSITY (US) 2022-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382629-A1 HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN FAP, FIBP, FOLH1 MAPK1 3078/4885SLC18A3 3065/4885KCNQ3 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.